Aura Biosciences (AURA) Stock Forecast: StockMap's 2-Week Call
AURA stock forecast: StockMap's model makes no two-week call on Aura Biosciences after the Nov 19 close: its evidence is split, 4 reasons for and 11 against. Right in 3 of 6 two-week windows on AURA since Aug 21; by chance, a call on the same dates was right 58% of the time.
Aura Biosciences last closed at $6.98, -2.24% on the session.
Against the IVW growth benchmark the position is +0.09% over the forecast window.
Aura Biosciences' market cap is $726.44M as of November 19, 2026.
No call today: the model sees no clear direction · the next 2 weeks, vs S&P 500 growth. The lean on a scale from −100 to +100 is -15 (too close to call).
Where AURA sits: sized by market cap, coloured by the day's move.
The read is built from 15 underlying insights — 4 bullish and 11 bearish.
Agreement across those insights is 73%.
44 daily calls for AURA so far. We publish our accuracy across thousands of stocks in the open, misses included — no per-stock hit rate is claimed on a small sample.
On the fundamentals StockMap ranks Aura Biosciences in the 14th percentile on return on equity, where 100 is best.
Aura Biosciences is classified under Health Care / Biotechnology.
StockMap tracks Aura Biosciences as the 145th largest of the 394 companies it covers in the Biotechnology industry, part of the Health Care sector.
Across that group the current two-week reads are 200 Moderate Underperform, 134 Neutral, 43 Strong Underperform and 17 Moderate Outperform.
On that composite Aura Biosciences ranks 130th of 394 in the group, against a group median of -0.27.